Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemcitabine (Primary) ; Ivospemin (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Panbela Therapeutics

Most Recent Events

  • 29 Sep 2024 This trial has been discontinued in Austria, according to European Clinical Trials Database record.
  • 04 Sep 2024 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
  • 24 Jun 2024 According to a Panbela Therapeutics media release, The DSMB recommended study continuation without modification, marking the third consecutive positive safety review.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top